Inclusion Criteria

Inclusion criteria:

- Signed informed consent

- Man or woman between 18 and 85 years of age

- Patients who will be receiving at least 2 more cycles of moderately emetogenic
chemotherapy

- Patients who are cognitively intact

- Performance Status of 60% or greater on the Karnofsky Scale

- Negative pregnancy test at screening visit in females of childbearing potential

- Use of appropriate contraceptive methods for females of childbearing potential during
treatment (e.g. hormonal contraception, intrauterine device [IUD])

Exclusion Criteria:

- A history of psychiatric illness.

- A history of asthma and any other chronic respiratory illness.

- Subjects who, in the judgment of the investigator, are likely to be non-compliant or
uncooperative during the study.

- Serious illnesses such as asthma, diabetes mellitus, active peptic ulcer disease,
infection, cardiovascular disease or any other disease which may affect the oucome
parameters of this study

- Abnormal liver function tests (ALT, AST or AP > 2.5 x upper normal limit)

- Abnormal renal function (e.g. serum creatinine > 2 x upper normal limit)

- Abnormal pulmonary function test which in the judgment of the investigator is
incompatible with inhalation of the study drug

- Known intolerance/hypersensitivity to study drugs (THC, ondansetron or dexamethasone)
or drugs of similar chemical structure or pharmacological profile

- History of addiction to alcohol or drugs

- Existing or intended pregnancy or lactation

- Participation in another clinical trial within the last 30 days, simultaneous
participation in another clinical trial, or previous participation in this trial